Regeneron Q3 revenue jumps 36.3% to $5.12B; net income up 33.5% to $1.95B

Filed October 30, 2026 · Period ending September 30, 2026 · Compared to 10-Q Oct 28, 2025 · ~1 min read

Key Changes

• high

  Total revenue rose 36.3% to $5.12B, driven by Dupixent and EYLEA HD; net income climbed 33.5% to $1.95B, with diluted EPS up 35.5% to $18.45.

  MD&A: Revenue & Net Income verify on EDGAR →
• high

  Sanofi collaboration amended in October 2026: $1.0B upfront payment received, up to $7.0B in milestones for four new long-acting antibodies.

  Notes: Sanofi Collaboration verify on EDGAR →
• high

  New U.S. government agreements impose Most-Favored-Nation pricing on certain wholly-owned products for Medicaid, plus free Otarmeni gene therapy and tariff protection through January 2029.

  MD&A: U.S. Government Agreements verify on EDGAR →